Search - tctmd.com

Displaying 1 - 20 of 531

Sort: Relevancy | Date

Presentation ACC 2026

The STEMI Door to Unload Trial (STEMI-DTU)

Presenter: Gregg Stone

March 28, 2026

Presentation THT 2026

The Elephant in the Room: How To Deal With PROs in Non-Sham Controlled Studies

Presenter: Gregg W. Stone

March 04, 2026

Presentation THT 2026

Clinical Evaluation Of The Vsling™ Device For Ventricular Repair In Patients With Heart Failure

Presenter: Gregg W. Stone

March 03, 2026

Presentation THT 2026

NO: The Evidence is Not Strong Enough to Support TEER in Moderate MR in HF

Presenter: Gregg W. Stone

March 02, 2026

Presentation TCT 2025

Primary Results from the ATHENS-HF Trial: An FIH Study of the Chronically-Adjustable, Biatrial Pressure Sensing Interatrial Shunt (Adona Medical)

Presenter: Gregg W. Stone

October 28, 2025

Presentation TCT 2025

Should Sham Control vs Open Trial Design Make a Difference for Device Regulators and Guideline Makers?

Presenter: Gregg W. Stone

October 28, 2025

Presentation TCT 2025

M-TEER in Secondary MR: What the Clinical Evidence Shows

Presenter: Gregg W. Stone

October 27, 2025

Presentation TCT 2025

TCT 531: Early Clinical Experience with a Chronically-Adjustable, Biatrial Pressure Sensing Interatrial Shunt for Heart Failure: Adona Medical

Presenter: Gregg W. Stone

October 27, 2025

Presentation TCT 2025

Position 1: DES

Presenter: Gregg W. Stone

October 26, 2025

Presentation NY Valves 2025

Mitral TEER in Symptomatic FMR: Emerging Data and Futuristic Trends

Presenter: Gregg W. Stone

June 25, 2025

Presentation THT 2025

Evidence That Challenges the Validity of KCCQ as a Measure of Quality of Life in Both Blinded and Unblinded Studies

Presenter: Gregg Stone

February 13, 2025

Presentation THT 2025

Predictors of Outcomes After Inter-atrial Shunt Treatment in HFrEF and HFpEF: The RELIEVE-HF trial

Presenter: Gregg W. Stone

February 11, 2025

Presentation TCT 2024

Vulnerable Plaque: What’s Next?

Presenter: Gregg Stone

October 30, 2024

Presentation TCT 2024

OCCUPI

Presenter: Gregg Stone

October 30, 2024

Presentation TCT 2024

The Most Interesting ‘M-TEER in SMR’ Studies of 2024

Presenter: Gregg Stone

October 29, 2024

Presentation ACC 2024

Principal Results From the Double-blind, Placebo-controlled ULTIMATE-DAPT Trial

Presenter: Gregg W Stone

April 07, 2024

Presentation ACC 2024

Principal Results from the RELIEVE-HF Trial

Presenter: Gregg W. Stone

April 06, 2024

Presentation TCT 2023

Addressing Microvascular Obstruction with SSO2

Presenter: Gregg Stone

October 25, 2023

Presentation TCT 2023

Bivalirudin Is the Most Evidence Based Antithrombin Agent for Primary PCI

Presenter: Gregg Stone

October 25, 2023

Presentation ESC 2023

Intravascular Imaging Guidance for PCI: A “Real-Time” Updated Network Meta-analysis

Presenter: Gregg W. Stone

August 28, 2023

Advertisement

The STEMI Door to Unload Trial (STEMI-DTU)

The Elephant in the Room: How To Deal With PROs in Non-Sham Controlled Studies

Clinical Evaluation Of The Vsling™ Device For Ventricular Repair In Patients With Heart Failure

NO: The Evidence is Not Strong Enough to Support TEER in Moderate MR in HF

Primary Results from the ATHENS-HF Trial: An FIH Study of the Chronically-Adjustable, Biatrial Pressure Sensing Interatrial Shunt (Adona Medical)

Should Sham Control vs Open Trial Design Make a Difference for Device Regulators and Guideline Makers?

M-TEER in Secondary MR: What the Clinical Evidence Shows

TCT 531: Early Clinical Experience with a Chronically-Adjustable, Biatrial Pressure Sensing Interatrial Shunt for Heart Failure: Adona Medical

Position 1: DES

Mitral TEER in Symptomatic FMR: Emerging Data and Futuristic Trends

Evidence That Challenges the Validity of KCCQ as a Measure of Quality of Life in Both Blinded and Unblinded Studies

Predictors of Outcomes After Inter-atrial Shunt Treatment in HFrEF and HFpEF: The RELIEVE-HF trial

Vulnerable Plaque: What’s Next?

OCCUPI

The Most Interesting ‘M-TEER in SMR’ Studies of 2024

Principal Results From the Double-blind, Placebo-controlled ULTIMATE-DAPT Trial

Principal Results from the RELIEVE-HF Trial

Addressing Microvascular Obstruction with SSO2

Bivalirudin Is the Most Evidence Based Antithrombin Agent for Primary PCI

Intravascular Imaging Guidance for PCI: A “Real-Time” Updated Network Meta-analysis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content